

**INNOVATIVE ASTHMA MANAGEMENT BY  
COMMUNITY PHARMACISTS IN AUSTRALIA**

---

**Vicky Kritikos**

**B Pharm, M Pharm (Clinical)**

**A thesis submitted in fulfilment of the requirements for the  
degree of Doctor of Philosophy**

**Faculty of Pharmacy**



**The  
University  
of Sydney**

**March 2007**

***I wish to dedicate this thesis to my husband  
Stavros  
and my late brother  
Michael***

## **DECLARATION**

The research presented in this thesis was carried out under the supervision of Dr Sinthia Bosnic-Anticevich and Prof Carol Armour, within the Faculty of Pharmacy, University of Sydney. To the best of my knowledge, the work presented in this thesis is original, except as acknowledged in the text. Full acknowledgments have been made wherever the work of others has been used. This thesis has not been submitted in part or in whole for the award of a degree at any other University.

Vicky Kritikos  
BPharm, MPharm (Clinical)

## **ACKNOWLEDGEMENTS**

I am privileged to have been given the opportunity to do my PhD amongst researchers of the highest calibre in the Faculty of Pharmacy, University of Sydney. These people have been instrumental in supporting and assisting me throughout my PhD. I would like to thank the following people who have each had a special part to play in the completion of this thesis:

Dr Sinthia Bosnic-Anticevich and Prof Carol Armour. Thank you for your kindness, guidance, enthusiasm, patience and the unwavering support you have given me during the time taken to complete my degree. It is deeply appreciated and shall never be forgotten.

Dr Bandana Saini and Associate Prof Ines Krass. Thank you for your support and advice, and willingness to assist me in my hour of need on this incredible journey.

Dr Tim Chen and Prof Andrew McLachlan. Thank you for your support and the inspiration and encouragement you have given me throughout my research.

Prof Iqbal Ramzan. Thank you for your friendship and the support and assistance you have given me during my candidature.

Dr Smita Shah and the AIM project team. Thank you for your valuable time, enthusiastic input and collaboration during my research.

Associate Prof Ellen Sørensen and the Danish pharmacists. Thank you for your collaboration with Pharmacy Practice and the sharing of ideas during my research.

Fran Everingham and Hui Shen Chan. Thank you for your valuable contribution, assistance, and support during my research.

Erica Sainsbury and Dr Celina Seeto. Thank you for your sense of humour, support and encouragement. You are special people and I will always cherish you both.

Commonwealth Department of Health and Ageing. Thank you for the funding under the Asthma Innovative Management Program for the AIM project in Orange, NSW.

Dr Helen Watt. Thank you for the guidance and advice and the inspiration and encouragement you have given me over the years. You have been instrumental in preserving my sanity throughout my PhD.

Bek, Michelle, Alison, Geraldine, Cassie and Simon. Thank you for your friendship, help and support. You have been such fantastic role models and have inspired me throughout my journey. You have made me feel like one of your own.

Diana and Kee Chi. Thank you for your love and concern and for being there when I needed you most. This friendship will be treasured forever.

Glena, Tipaporn, Kristy and Pradnya. Thank you for being there and for sharing all the ups and downs during the final stages of my PhD.

The community pharmacists especially Frances Hulme, medical practitioners, high school staff, local media and the community in Orange, NSW. Thank you for your input and the overwhelming support during the AIM project.

The staff at the Thoracic Society of Australia and New Zealand. Thank you for the assistance and continual support throughout my research.

The pharmacists, respiratory physicians and participants in the studies. Thank you for your invaluable time, input and support with my research.

The community pharmacists, Gulian, Paul, Leah, Michael, Linda, Cheryl and Jodie, and Dr Raj. Thank you for your understanding, input and support during my PhD.

Judith Seguna and Harry Eric Abrook. Thank you for all the support, the love, the memories and the laughter. I will always cherish these forever.

All my close family members, Aunty Ester, Millie, Paul, Afroula, Angie, Mary and all my good friends. Thank you for your understanding, patience and encouragement.

My brother Tassie, my sister Maria and my beloved parents and brother Michael. Thank you for your encouragement and having such incredible faith in me. Without your encouragement and faith I would not have been able to complete this degree.

And finally, to my pillar of support, my dearly beloved and selfless husband Stavros. Thank you for *everything* – thank you for standing by me. I could not have completed this thesis without your love and understanding, patience and support.

Vicky

## PREFACE

This thesis describes research carried out between 2002 and 2005, which was based on the latest international [Global Initiative for Asthma (GINA) Workshop Report, *Global Strategy of Asthma Management and Prevention*] and national asthma management guidelines [National Asthma Council (NAC) *Asthma Management Handbook 2002*] at the time. Revised international GINA guidelines (NHLBI/WHO 2006) and Australian asthma management guidelines (National Asthma Council 2006) were published in 2006 during the final preparation stages of this thesis.

## **PUBLICATIONS AND COMMUNICATIONS**

### **Peer-reviewed journal articles**

Kritikos V, Saini B, Bosnic-Anticevich SZ, Krass I, Shah S, Taylor S, Armour C. Innovative asthma health promotion by rural community pharmacists: a feasibility study. *Health Promotion Journal of Australia* 2005;16(1): 69-73.

Kritikos V, Krass I, Chan HS, Bosnic-Anticevich SZ. The validity and reliability of two asthma knowledge questionnaires. *Journal of Asthma* 2005;42: 795-801.

Kritikos V, Armour CL, Bosnic-Anticevich SZ. Interactive small-group asthma education in the community pharmacy setting: a pilot study. *Journal of Asthma* 2007;44: 57-64.

### **External conference presentations**

Kritikos V, Saini B, Bosnic-Anticevich SZ, Shah S, Krass I, Dalton A, Hulme F, Armour C. Innovative asthma health promotion by rural community pharmacists: a feasibility study.

-podium presentation at the Australasian Pharmaceutical Science Association (APSA) Annual Conference 2003 (Sydney, Australia).

Kritikos V, Saini B, Bosnic-Anticevich SZ, Shah S, Krass I, Taylor S, Dalton A, Hulme F, Armour C. Rural community pharmacists and asthma health promotion.

-podium presentation at the Woolcock Institute of Medical Research, Royal Prince Alfred Hospital. Friday Morning Research Meetings 2003 (Sydney, Australia).

Kritikos V, Saini B, Bosnic-Anticevich SZ, Shah S, Krass I, Dalton A, Hulme F, Armour C. Innovative asthma health promotion by rural community pharmacists: a feasibility study.

-podium presentation at the University of Sydney 4th College of Health Sciences and Medical Research Conference 2004 "From Cell to Society" (Leura, Australia).

Kritikos V, Saini B, Bosnic-Anticevich SZ, Shah S, Krass I, Taylor S, Dalton A, Hulme F, Armour C. Asthma outreach programs provided by rural community pharmacists: a feasibility study.

-podium presentation at the International Primary Care Respiratory Group (IPCRG) 2<sup>nd</sup> World Conference 2004 (Melbourne, Australia).

Kritikos V, Saini B, Bosnic-Anticevich SZ, Shah S, Krass I, Dalton A, Hulme F, Armour C. Asthma outreach programs provided by rural community pharmacists: a feasibility study.

-podium presentation at the Pharmaceutical Society of Australia (PSA) NSW Young Pharmacists' Conference 2004 (Sydney, Australia).

Kritikos V, Krass I, Chan HS, Bosnic-Anticevich SZ. The validity and reliability of two asthma knowledge questionnaires.

-poster presentation at the Australasian Pharmaceutical Science Association (APSA) Annual Conference 2004 (Melbourne, Australia).

Kritikos V, Krass I, Chan HS, Bosnic-Anticevich SZ. The validity and reliability of two asthma knowledge questionnaires.

-poster presentation at the 13<sup>th</sup> International Social Pharmacy Workshop (ISPW) 2004 (Malta).

Kritikos V, Saini B, Bosnic-Anticevich SZ, Shah S, Krass I, Dalton A, Hulme F, Armour C. Asthma outreach programs provided by rural community pharmacists: a feasibility study.

-podium presentation by C Armour at the 13<sup>th</sup> International Social Pharmacy Workshop (ISPW) 2004 (Malta).

Kritikos V, Armour CL, Bosnic-Anticevich SZ. Interactive small-group asthma education in the community pharmacy setting: a pilot study.

-podium presentation by SZ Bosnic-Anticevich at the 14<sup>th</sup> International Social Pharmacy Workshop (ISPW) 2006 (Oxford).

-podium presentation by SZ Bosnic-Anticevich at the European Respiratory Society 16<sup>th</sup> Annual Congress 2006 (Munich).

Kritikos V, Armour CL, Bosnic-Anticevich SZ. Interactive small-group asthma education in the community pharmacy setting: a pilot study.

-podium presentation at the Australian Asthma Conference 2006 (Adelaide, Australia).

Kritikos V, Armour CL, Bosnic-Anticevich SZ. Interactive small-group asthma education in the community pharmacy setting: a pilot study.

-podium presentation at the University of Sydney 5th College of Health Sciences and Medical Research Conference 2006 "From Cell to Society" (Leura, Australia).

Kritikos V, Armour CL, Bosnic-Anticevich SZ. Innovative asthma management by community pharmacists in Australia.

-podium presentation at the Woolcock Institute of Medical Research, Royal Prince Alfred Hospital. Friday Morning Research Meetings 2006 (Sydney, Australia).

### **Internal faculty presentations**

Kritikos V, Saini B, Bosnic-Anticevich SZ, Krass I, Armour C. The Asthma Innovative Management (AIM) Project.

-podium presentation at the Faculty of Pharmacy for the AIM Steering Committee Meeting 2003.

Kritikos V, Saini B, Bosnic-Anticevich SZ, Krass I, Armour C. The Asthma Innovative Management (AIM) Project.

-podium presentation at the Faculty of Pharmacy Postgraduate Work-in-Progress (2003).

Kritikos V, Bosnic-Anticevich SZ, Armour C. Community pharmacists, health promotion and asthma.

-podium presentation at the Faculty of Pharmacy Postgraduate Work-in-Progress (2004).

Kritikos V, Saini B, Bosnic-Anticevich SZ, Krass I, Armour C. The Asthma Innovative Management (AIM) Project.

-poster presentation at the Faculty of Pharmacy Research Day (2004).

Kritikos V, Krass I, Chan HS, Bosnic-Anticevich SZ. The validity and reliability of two asthma knowledge questionnaires.

-poster presentation at the Faculty of Pharmacy Research Day (2005).

Kritikos V, Armour CL, Bosnic-Anticevich SZ. Innovative asthma management by community pharmacists in Australia.

-podium presentation at the Faculty of Pharmacy Seminar Series (2006).

## TABLE OF CONTENTS

Declaration	iii
Acknowledgements	iv
Preface	vi
Publications and communications	vii
Table of contents	x
List of tables	xv
List of figures	xvii
List of appendices	xviii

### **CHAPTER 1: ASTHMA AND THE ROLE OF COMMUNITY PHARMACISTS IN ASTHMA MANAGEMENT: A REVIEW OF THE LITERATURE**

---

<b>1.1. INTRODUCTION</b>	<b>1</b>
<b>1.2. ASTHMA</b>	<b>1</b>
<b>1.3. FACTORS INFLUENCING THE DEVELOPMENT OF ASTHMA</b>	<b>2</b>
1.3.1. Host factors	2
1.3.1.1. Genetic predisposition	2
1.3.1.2. Obesity	3
1.3.1.3. Gender	3
1.3.2. Environmental factors	3
1.3.2.1. Allergens	3
1.3.2.2. Infections	4
1.3.2.3. Occupational sensitisers	4
1.3.2.4. Tobacco smoke	4
1.3.2.5. Outdoor/indoor air pollution	5
1.3.2.6. Diet	5
<b>1.4. CLASSIFICATION OF ASTHMA</b>	<b>5</b>
1.4.1. Global classification of asthma	5
1.4.2. Australian classification of asthma	5
<b>1.5. EPIDEMIOLOGY OF ASTHMA</b>	<b>6</b>
1.5.1. Asthma prevalence	6
1.5.2. Asthma mortality	8
1.5.3. Impact of asthma	9
1.5.3.1. Impact of asthma on health care utilisation in Australia	10
1.5.3.2. Impact of asthma on quality of life in Australia	11
1.5.3.3. Economic impact of asthma	12

<b>1.6.</b>	<b>ASTHMA MANAGEMENT IN AUSTRALIA</b>	<b>14</b>
1.6.1.	A brief history	14
1.6.2.	The role of the National Asthma Council	15
1.6.3.	The role of the State Asthma Foundations and Asthma Australia	17
1.6.3.1.	The Asthma Foundations	17
1.6.3.2.	Asthma Australia	17
<b>1.7.</b>	<b>ASTHMA MANAGEMENT GUIDELINES</b>	<b>17</b>
1.7.1.	Global asthma management guidelines	17
1.7.2.	Australian asthma management guidelines	18
1.7.3.	Evidence-based review of the Australian Asthma Management Plan	22
<b>1.8</b>	<b>CURRENT ISSUES IN ASTHMA MANAGEMENT</b>	<b>25</b>
1.8.1.	Patient related issues	25
1.8.2.	Health care professional related issues	29
1.8.3.	Public health related issues	32
<b>1.9.</b>	<b>ASTHMA EDUCATION</b>	<b>32</b>
1.9.1.	Effective asthma education for adults	33
1.9.1.1.	Components of the asthma education program	33
1.9.1.2.	Factors associated with the delivery of the education	37
1.9.1.3.	Setting for the education	40
<b>1.10.</b>	<b>EVALUATION OF THE EDUCATION</b>	<b>46</b>
1.10.1.	The impact of education on asthma knowledge	46
<b>1.11.</b>	<b>ASTHMA AND COMMUNITY PHARMACISTS</b>	<b>48</b>
1.11.1.	Community pharmacy-based asthma care programs	49
<b>1.12.</b>	<b>HEALTH PROMOTION AND COMMUNITY PHARMACISTS</b>	<b>50</b>
1.12.1.	Community pharmacy-based health promotion activities	50
<b>1.13.</b>	<b>OPPORTUNITY STATEMENT</b>	<b>51</b>
<b>1.14.</b>	<b>SCOPE AND AIMS</b>	<b>52</b>
<b>CHAPTER 2: ASTHMA HEALTH PROMOTION AND THE ROLE OF THE PHARMACIST</b>		<b>53</b>
<hr/>		
<b>2.1.</b>	<b>INTRODUCTION</b>	<b>53</b>
<b>2.2.</b>	<b>OBJECTIVES</b>	<b>54</b>
<b>2.3.</b>	<b>METHODS</b>	<b>54</b>
2.3.1.	Study design	54
2.3.2.	Recruitment of pharmacists	55
2.3.3.	Recruitment of high schools	55

2.3.4.	Adolescent health promotion	57
2.3.4.1.	Training of pharmacists	57
2.3.4.1.1.	Evaluation of training	58
2.3.4.2.	Delivery of Triple A program	58
2.3.4.2.1.	Evaluation by students	58
2.3.4.2.2.	Evaluation by pharmacists	58
2.3.4.2.3.	Evaluation by school staff	58
2.3.4.3.	Media promotion	58
2.3.5.	Community based health promotion	60
2.3.5.1.	Pharmacist training workshop	60
2.3.5.1.1.	Evaluation of the training	60
2.3.5.2.	Public forum	60
2.3.5.2.1.	Evaluation by attendees	61
2.3.5.3.	Media promotion	61
2.3.6.	Data collection from pharmacies	61
2.3.6.1.	Data collection form	61
2.3.6.2.	Semi-structured interviews with pharmacists	61
2.3.6.3.	Dispensary records of asthma medications	62
2.3.7.	Steering committee	62
2.3.8.	Establishment of local support network	62
<b>2.4.</b>	<b>DATA ANALYSIS</b>	<b>62</b>
2.4.1.	Quantitative data	62
2.4.2.	Semi-structured interviews	63
<b>2.5.</b>	<b>RESULTS</b>	<b>65</b>
2.5.1.	Evaluation of adolescent health promotion	65
2.5.1.1.	Evaluation of Triple A training by pharmacists	65
2.5.1.2.	Evaluation of Triple A delivery	66
2.5.1.2.1.	Evaluation of Triple A by Year 11 students and pharmacists	66
2.5.1.2.2.	Evaluation of Triple A by high school staff	67
2.5.2.	Evaluation of community based health promotion	68
2.5.2.1.	Evaluation of workshop by pharmacists	68
2.5.2.2.	Evaluation of public forum	69
2.5.3.	Impact of health promotion activities	70
2.5.3.1.	Semi-structured interviews	70
2.5.3.2.	Triangulation of data at baseline	72
2.5.3.3.	Quantitative data from pharmacies	72

<b>2.6.</b>	<b>DISCUSSION</b>	<b>74</b>
2.6.1.	Future directions	79
<b>2.7.</b>	<b>CONCLUSIONS</b>	<b>79</b>
<b>CHAPTER 3: THE DEVELOPMENT AND EVALUATION OF TWO ASTHMA KNOWLEDGE QUESTIONNAIRES</b>		<b>81</b>
<b>3.1.</b>	<b>INTRODUCTION</b>	<b>81</b>
<b>3.2.</b>	<b>OBJECTIVES</b>	<b>82</b>
<b>3.3.</b>	<b>METHODS</b>	<b>83</b>
3.3.1.	Development of the questionnaires	83
3.3.2.	Reliability and validity	84
3.3.3.	Pilot testing of the questionnaires	85
3.3.3.1.	Study subjects for the pilot study	86
3.3.4.	Main study	86
3.3.4.1.	Study subjects for the main study	86
<b>3.4.</b>	<b>DATA ANALYSIS</b>	<b>86</b>
3.4.1.	Content and face validity	86
3.4.1.1.	Readability of the instruments	87
3.4.2.	Construct validity	87
3.4.3.	Criteria-related validity	87
3.4.3.1.	Discriminant analysis	88
3.4.4.	Reliability	88
3.4.4.1.	Internal consistency	88
<b>3.5.</b>	<b>RESULTS</b>	<b>88</b>
3.5.1.	Pilot study	88
3.5.1.1.	Sample size	89
3.5.2.	Main study	89
3.5.2.1.	Validity	90
3.5.2.1.1.	Content and face validity	90
3.5.2.1.2.	Construct validity	90
3.5.2.1.3.	Criteria-related validity	92
3.5.2.2.	Reliability	95
3.5.2.2.1.	Internal consistency	95
<b>3.6.</b>	<b>DISCUSSION</b>	<b>95</b>
3.6.1.	Future directions	99
<b>3.7.</b>	<b>CONCLUSIONS</b>	<b>100</b>



## LIST OF TABLES

Table 1.1.	Classification of asthma severity based on NAC guidelines	6
Table 1.2.	Maintenance medications for adults	20
Table 1.3.	Dose titration for maintenance therapy	21
Table 1.4.	Systematic review of the six-step asthma management plan	24
Table 1.5.	Summary characteristics of the 12 trials included in the Cochrane systematic review (Gibson <i>et al</i> 1998a)	35
Table 1.6.	Summary characteristics of the 36 trials included in the Cochrane systematic review (Gibson <i>et al</i> 1999)	36
Table 1.7.	Characteristics of small-group asthma education intervention for adults	39
Table 1.8.	Effects of adult asthma self-management education interventions conducted in primary care	41
Table 1.9.	Characteristics of published asthma knowledge questionnaires	47
Table 2.1.	Program strategy	64
Table 2.2.	Proportion of total students in a particular year that were trained	65
Table 2.3.	Evaluation of the Triple A training by pharmacists and Year 11 students	67
Table 2.4.	Pharmacist evaluation of the workshops and resources	68
Table 2.5.	Pharmacist evaluation of the training workshop	69
Table 2.6.	Rating of public forum activities by attendees	70
Table 2.7.	Perceptions of the public forum by attendees	70
Table 2.8.	Asthma-related activity at baseline and post health promotion activities	73
Table 3.1.	Comparison of mean total score obtained on the CQ for people without asthma, people with asthma and fourth year pharmacy students. Maximum possible score is 14 (n = 129)	89
Table 3.2.	Comparison of mean total score obtained on the HQ for people without asthma, people with asthma and fourth year pharmacy students. Maximum possible score is 20 (n = 129)	89
Table 3.3.	Principal component estimates of the direct oblimin factor loadings for the 12-item CQ (n = 505)	91
Table 3.4.	Principal component estimates of the direct oblimin factor loadings for the 18-item CQ (n = 505)	92
Table 3.5.	Comparison of mean total score obtained on the CQ for people without asthma, people with asthma, pharmacists and respiratory physicians. Maximum possible score is 12 (n = 505)	93
Table 3.6.	Comparison of responses to individual items of the CQ completed by people without asthma, people with asthma, pharmacists, respiratory physicians. Number (%) of subjects responding correctly	93

Table 3.7.	Comparison of mean total score obtained on the HQ for people without asthma, people with asthma, pharmacists and respiratory physicians. Maximum possible score is 18 (n = 505)	94
Table 3.8.	Comparison of responses to individual items of the HQ completed by people without asthma, people with asthma, pharmacists, respiratory physicians. Number (%) of subjects responding correctly	94
Table 4.1.	Demographic indicators for areas selected	110
Table 4.2.	Baseline characteristics of the three groups	111
Table 4.3.	MARS, quality of life, asthma knowledge and optimal inhaler technique at baseline	112
Table 4.4.	Total asthma quality of life (AQOL) scores for the three groups	119
Table 4.5.	MARS scores for the three groups	119

## LIST OF FIGURES

Figure 2.1.	Study design	56
Figure 2.2.	The three-step process	57
Figure 2.3.	Project and promotional activities timeline	59
Figure 2.4.	Mean asthma knowledge scores of Year 11 students in each high school pre and post Triple A training	66
Figure 2.5.	Asthma-related pharmacy visits at four different time points	74
Figure 3.1.	Study design	83
Figure 4.1.	Study design	103
Figure 4.2.	Steps in health promotion program planning and evaluation	106
Figure 4.3.	Median asthma knowledge (interquartile range) scores for Group A (pharmacist-led), Group B (asthma educator-led) and Group C (usual care) at baseline (pre), immediately after education (post), and at 6 weeks (Visit 2) and 12 weeks (Visit 3) follow up	113
Figure 4.4.	The proportion (%) of subjects demonstrating optimal MDI technique in Group A (pharmacist-led), Group B (asthma educator-led) and Group C (usual care) at baseline (pre), immediately after education (post), and at 6 weeks (Visit 2) and 12 weeks (Visit 3) follow up	114
Figure 4.5.	The proportion (%) of subjects demonstrating optimal DPI technique in Group A (pharmacist-led), Group B (asthma educator-led) and Group C (usual care) at baseline (pre), immediately after education (post), and at 6 weeks (Visit 2) and 12 weeks (Visit 3) follow up	115
Figure 4.6.	The proportion (%) of subjects in each asthma severity/control category at baseline, and at 6 weeks (Visit 2) and 12 weeks (Visit 3) follow up for Group A (pharmacist-led) (n=16)	116
Figure 4.7.	The proportion (%) of subjects in each asthma severity/control category at baseline, and at 6 weeks (Visit 2) and 12 weeks (Visit 3) follow up for Group B (asthma educator-led) (n=16)	117
Figure 4.8.	The proportion (%) of subjects in each asthma severity/control category at baseline, and at 6 weeks (Visit 2) and 12 weeks (Visit 3) follow up for Group C (usual care) (n=16)	118

## LIST OF APPENDICES

Appendix 1	Ethics approval for strategy 1	A1
Appendix 2	Pharmacist information and consent form	A2
Appendix 3	Letters to high schools	A4
Appendix 4	Triple A educators training workshop	A8
Appendix 5	Asthma knowledge questionnaire	A9
Appendix 6	Student information and consent form	A12
Appendix 7	Asthma peer leaders' evaluation questionnaire	A14
Appendix 8	Triple A educators' evaluation questionnaire	A15
Appendix 9	Teachers' feedback	A17
Appendix 10	Local newspaper articles	A18
Appendix 11	Pharmacists' second training workshop	A20
Appendix 12	Pharmacists' workshop program	A21
Appendix 13	Pharmacists' evaluation of the second training workshop	A22
Appendix 14	Exit survey for the public forum	A24
Appendix 15	Media promotion of the public forum	A26
Appendix 16	Data collection form for asthma-related pharmacy visits	A32
Appendix 17	Objectives for semi-structured interviews	A33
Appendix 18	Pilot 23-item CQ	A34
Appendix 19	Pilot 41-item HQ	A36
Appendix 20	Ethics approval for pilot study	A39
Appendix 21	Ethics approval for main study	A40
Appendix 22	The 14-item CQ	A42
Appendix 23	The 20-item HQ	A43
Appendix 24	The 12-item CQ	A45
Appendix 25	The 18-item HQ	A46
Appendix 26	Ethics approval for strategy 2	A48
Appendix 27	Participant information and consent Group A	A50
Appendix 28	Program guidelines	A52
Appendix 29	Baseline data collection	A59
Appendix 30	Post education data collection	A69
Appendix 31	Data collection at Visit 2	A71
Appendix 32	Patient satisfaction questionnaire	A79
Appendix 33	Data collection at Visit 3	A82
Appendix 34	Workshop training program	A90
Appendix 35	Facilitators' guide for workshop	A91
Appendix 36	Pharmacists' evaluation	A95